On 9/11/2023, the FDA approved and authorized updated Moderna and Pfizer COVID-19 vaccines formulated to more closely target currently circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death. These vaccines have been updated to include a monovalent (single) component that corresponds to the Omicron variant XBB.1.5. On 9/12/2023, ACIP recommended 2023–2024 (monovalent, XBB containing) COVID-19 vaccines as authorized under Emergency Use Authorization (EUA) or approved by Biologics License Application (BLA) in persons ≥6 months of age. A short time later, CDC Director Mandy Cohen signed off on the recommendation. Please watch all resources (ie., CDC, Immunize.org, AAP), for updated materials and clinical guidance. 2023 – 2024 (monovalent, XBB containing) mRNA COVID-19 vaccine recommendations: · Everyone ages 5 years and older is recommended to receive 1 dose of a 2023–2024 mRNA COVID-19 vaccine · Children ages 6 months–4 years should complete a multi-dose initial series (2 doses of Moderna or 3 doses of Pfizer-BioNTech mRNA COVID-19 vaccine) with at least one dose of the 2023–2024 COVID-19 vaccine · People who are moderately or severely immunocompromised should complete a 3- dose initial series with at least one dose of the 2023–2024 COVID-19 vaccine and may receive 1 or more additional 2023–2024 COVID-19 vaccine doses · Bivalent mRNA COVID-19 vaccines are no longer recommended in the United States |